EMERYVILLE, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will host an update call on Dravet syndrome and the Company’s investigational drug, ZX008, featuring pediatric epilepsy expert, Joseph Sullivan, M.D., on Monday, December 4, 2017, at 4:30pm Eastern Time.
Dr. Sullivan is Director of the Pediatric Epilepsy Center at University of California San Francisco, and the Principal Investigator of Zogenix’s first Phase 3 trial (Study 1) in North America for ZX008 for Dravet syndrome. He will discuss the current treatment landscape, the unmet medical need for treating patients with Dravet syndrome and the updated Phase 3 clinical trial data on ZX008 to be presented at the upcoming American Epilepsy Society (AES) 71st Annual Meeting. Dr. Sullivan will be available to answer questions at the conclusion of the call.
Zogenix's management team will also provide a summary of the information from other Company-sponsored posters to be presented at AES.
Dr. Joseph Sullivan, a pediatric epileptologist, is an associate professor of neurology and pediatrics, and the director of the UCSF Pediatric Epilepsy Center at Benioff Children’s Hospital, where he specializes in the evaluation and treatment of children with medically refractory epilepsy. He has particular clinical and research interests in Dravet Syndrome and PCDH19 related epilepsy and follows large cohorts of children with these specific epilepsy syndromes. Dr. Sullivan is a member of the Dravet Syndrome Foundation Medical Advisory Board, Chair of the PCDH19 Alliance Scientific Advisory board, and a member of the Pediatric Epilepsy Research Consortium Steering Committee, which brings together pediatric epilepsy centers across the United States to collaborate on various studies in pediatric epilepsy. Prior to joining UCSF Benioff Children's Hospital in 2007, Dr. Sullivan completed residencies in pediatrics at Children's Memorial Hospital at Northwestern University where he spent an additional year as chief resident. He then completed his child neurology, clinical neurophysiology and epilepsy training at Children's Hospital of Philadelphia.
Zogenix (Nasdaq:ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options but face a critical need. For more information, visit www.zogenix.com.
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com
Source: Zogenix, Inc.